Clinical Trial

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

Name: AVTX-801 D-galactose Supplementation in SLC35A2-CDG — clinical trial record (NCT05402384)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG

Protocol Amendment History 8 amendments

This ClinicalTrials.gov record has been amended 8 times since 2022-05-28; most recent amendment 2026-06-25.

Trial Details

NCT Number	NCT05402384
Lead Sponsor	Eva Morava-Kozicz Collaborators: National Institute of Neurological Disorders and Stroke (NINDS), Rare Diseases Clinical Research Network, Children's Hospital of Philadelphia
Conditions	SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Enrollment	10 participants
Start Date	2027-01
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-29